Herpes Simplex Virus type 2 vaccine - Immorna
Alternative Names: HSV-2 vaccine - ImmornaLatest Information Update: 11 Sep 2024
At a glance
- Originator Immorna
- Class RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Herpes simplex virus infections
Most Recent Events
- 09 Aug 2024 Preclinical trials in Herpes simplex virus infections (Prevention) in China (Parenteral), prior to August 2024 (Immorna pipeline, August 2024)
- 07 Dec 2022 Immorna pharmaceuticals files a PCT patent application with WIPO for screening methods for lyophilizing RNA and mixing with a liquid LNP solution for Worldwide